Purple Biotech (NASDAQ/TASE: PPBT) reported financial results for the three and six months ended June 30, 2026, and highlighted new preclinical data for its CAPTN-3 tri-specific T-cell engager platform, led by IM1240, which is aimed to enter first-in-human clinical studies in 2027.
